Boston Scientific's $374 Penumbra Buyout Is Now Worth $317 Because 'Mo' Mahoney, Mo' Problems'

“Who amongst us hasn't promised 19% and finished with 1.35%?”

Every guy reading this right now: ¯\_(ツ)_/¯

Things you hate to see as an investor: ball buyout-premium shrinkage. Just ask anyone holding Penumbra, whose 19% takeover premium has shriveled to 1.35% before the deal even closes.

For context, back in January, Boston Scientific, agreed to buy the clot-sucking stroke-device maker for $374 a share. About 73% of that is straight cash, homie, and the rest is BSX stock. Just one problem: the stock part is a fixed number of BSX shares, no matter what BSX does.

And BSX, of course, did a lot. The Watchman heart-implant people spent 2026 getting their cheeks clapped, sliding ~55% from ~$96 at signing to $42.19 on Tuesday. Blame two guidance cuts on slowing Watchman sales, plus an August cyberattack that shut down every plant for eight days. For those of you keeping score at home, each Penumbra share now converts into $273.99 of cash plus 1.0354 BSX shares, or $317.68 total. That's 1.35% above PEN's $313.43 close the day before the deal, and $2.2B less than Penumbra holders were promised in January. Woof.

Now, you'd think the merger-arb crowd (read: hedge funds that buy the target, short the buyer and pocket the gap) would be sweating. The Federal Trade Commish has had this deal under a Second Request (read: the deep-dive antitrust review) since March. It also already killed one medtech deal this year (ask Edwards Lifesciences how that went).

Instead, PEN closed Tuesday 63 cents under deal value. That 0.2% spread pays less than parking cash for about three weeks, which usually means the smart money thinks it's done. And if the FTC c*ck blocks it anyway, Boston Sci owes Penumbra a $900M reverse breakup fee (roughly $22.85 a share's worth), or more than five times the premium on the actual deal. LOL.

Boston Sci CEO Mike Mahoney, meanwhile, didn’t hear no bell. On Wednesday, the company named 36-year lifer Joe Fitzgerald COO starting Jan. 1 and carved itself into three new segments, one of which "will include the Penumbra business following the anticipated close." It hasn't made an honest woman out of Penumbra yet, and it's already cleared out a drawer for her.

The crash did knock Boston Sci's total price tag down to ~$12.5B from $14.7B. It’s just that the cool $10.8B cash bill doesn't shrink. It's now 17.7% of BSX's $61.1B market cap (vs. ~8% at signing), funded partly by a $6B term loan.

To be fair, the bosses put their money where their mouths are. Mahoney spent ~$9M on Aug. 3 to buy the f*cking dip at $48.33 a share. Four directors bought between $45 and $57, and Fitzgerald moved $3M of his 401(k) into the stock. Spoiler: The dip kept dipping.

Regardless, Boston Sci is acting like the Commish already signed the marriage license. Your move, @FTC…

Until next time friends… 

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.